H.O.P.E: Helping Ovarian Cancer Patients Cope
Status: | Active, not recruiting |
---|---|
Conditions: | Ovarian Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 8/2/2018 |
Start Date: | April 2014 |
End Date: | April 2019 |
Pilot Study on H.O.P.E: Helping Ovarian Cancer Patients Cope During Disease Recurrence
The purpose of this study is to test the effect of the gynecologic oncologists with
palliative care specialist collaboration (GO-PC) intervention on patient quality of life.
palliative care specialist collaboration (GO-PC) intervention on patient quality of life.
Eligible patients include women diagnosed with platinum-resistant ovarian cancer or recurrent
ovarian cancer cancer. All patient participants will complete two quality of life (QOL)
questionnaires and a cost-diary documenting their health care experience at time of consent
and every 12 weeks thereafter. Consenting care givers will also be asked to complete two
questionnaires to asses the impact of structured palliative care on them every 12 weeks.
Patients will be assigned to two arms randomly: 1) usual care or 2) structured palliative
care. The primary endpoint is quality of life. A two-sided Chi-square test will be used to
compare the proportion of patients who have improved quality of life after treatment between
control arm and intervention arm. The average value of multiple scores after treatment will
be used to compare with the baseline score before treatment for each question in the standard
questionnaire.
ovarian cancer cancer. All patient participants will complete two quality of life (QOL)
questionnaires and a cost-diary documenting their health care experience at time of consent
and every 12 weeks thereafter. Consenting care givers will also be asked to complete two
questionnaires to asses the impact of structured palliative care on them every 12 weeks.
Patients will be assigned to two arms randomly: 1) usual care or 2) structured palliative
care. The primary endpoint is quality of life. A two-sided Chi-square test will be used to
compare the proportion of patients who have improved quality of life after treatment between
control arm and intervention arm. The average value of multiple scores after treatment will
be used to compare with the baseline score before treatment for each question in the standard
questionnaire.
Inclusion Criteria:
- Platinum-resistant ovarian cancer or recurrent ovarian cancer
- Ability to read and respond to questions in English
Exclusion Criteria:
- Platinum-sensitive recurrent ovarian cancer without a significant clinical event
- Existence of co-morbid disease, which in the opinion of the investigator prohibits
participation in the protocol
We found this trial at
2
sites
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Paula S Lee, MD
Phone: 919-668-6793
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
Click here to add this to my saved trials